Chemicals · Founded 2009 · www.chemfabalkalis.com · BSE 541269 · NSE CHEMFAB · ISIN INE783X01023
No Notes Added Yet
Business
Chemfab Alkalis Ltd. (CHEMFAB) is an Indian chemical company primarily engaged in the manufacturing of Chlor-Alkali products. Its core business revolves around producing essential industrial chemicals such as Caustic Soda (in liquid lye and solid flakes forms), Liquid Chlorine, Hydrogen, and various derivatives including Stable Bleaching Powder (SBP), Hydrochloric Acid (HCl), and Sodium Hypochlorite. The company generates revenue by supplying these bulk chemicals, which serve as critical raw materials for a wide range of industries including alumina, textiles, paper, soap & detergents, pharmaceuticals, agrochemicals, PVC manufacturing, and water treatment.
Revenue Mix
The company primarily operates as a single segment manufacturer of Chlor-Alkali products and their derivatives. While specific percentage contributions of individual products like Caustic Soda vs. Chlorine derivatives are typically not separately reported in detail, Caustic Soda and Liquid Chlorine are the flagship products, forming the bulk of its revenue. Derivatives such as Hydrochloric Acid and Sodium Hypochlorite offer product diversification and cater to specific customer needs.
Industry
The Indian Chlor-Alkali industry is an essential part of the broader chemicals sector, characterized by its energy-intensive nature and cyclical demand tied to end-user industries. The industry has a mix of large integrated players and smaller regional manufacturers. Chemfab Alkalis Ltd. is a mid-sized player in this segment, primarily serving the Southern Indian market. Its positioning is largely based on its operational scale, product quality, and established customer relationships within its geographical focus. The industry is competitive, with players often vying for cost efficiency due to the commoditized nature of basic chemicals.
MOAT
Chemfab Alkalis possesses some competitive advantages, though the commoditized nature of its products makes a strong moat challenging.
Cost Efficiency: The company has invested in modern, energy-efficient membrane cell technology for its production processes, which helps in reducing power consumption, a significant cost component in Chlor-Alkali manufacturing.
Backward Integration (Partial): Presence of captive power generation facilities (or long-term power purchase agreements) can mitigate power cost volatility to some extent.
Logistical Advantage: Being located near key raw material sources (salt) and target customer bases in Southern India can offer a cost advantage in transportation.
Established Relationships: Long-standing relationships with industrial customers provide a degree of revenue stability.
Growth Drivers
Industrial Growth: Demand for Chlor-Alkali products is directly linked to the growth of end-user industries like textiles, paper, alumina, infrastructure (PVC), and water treatment. Economic growth and increased industrialization in India will drive demand.
Capacity Expansion: Any ongoing or planned capacity expansions by Chemfab Alkalis will directly contribute to higher sales volumes.
Modernization & Efficiency: Continued investment in energy-efficient technologies (e.g., membrane cell technology upgrades) can improve profitability and competitiveness, supporting sustainable growth.
Diversification into Derivatives: Exploring and expanding into more value-added derivative products beyond basic chemicals could offer higher margins and new market opportunities.
Risks
Raw Material Price Volatility: Fluctuations in the prices of key raw materials like salt and energy (power, fuel) can significantly impact profit margins.
Cyclical Demand: The Chlor-Alkali industry is cyclical, heavily dependent on the performance of user industries. Economic downturns or slowdowns in sectors like textiles or paper can reduce demand and pricing power.
Intense Competition: The industry has multiple players, leading to price competition, which can erode margins, especially for commoditized products.
Environmental Regulations: The chemical industry is subject to stringent environmental regulations. Compliance costs, potential for fines, or mandated operational changes can pose risks.
Technology Obsolescence: While the company uses modern technology, continuous innovation and the need for capital-intensive upgrades to stay competitive is an ongoing challenge.
Management & Ownership
Chemfab Alkalis Ltd. is promoted by the N. Narayanan family, who have a long history in the Indian chemical industry. The company is professionally managed with a focus on operational efficiency and sustainable growth. The ownership structure typically features a significant promoter holding, indicating alignment of interests, alongside institutional and public shareholding. Information regarding specific corporate governance practices and management track record would require a deeper dive into annual reports and public filings.
Outlook
Chemfab Alkalis operates in a fundamental industry supplying essential chemicals. The outlook is balanced, influenced by India's broader industrial growth trajectory, which provides a secular demand tailwind for its products. Investments in energy-efficient technology and potential capacity expansions could drive volume and improve profitability. However, the company remains exposed to the inherent cyclicality of the chemical industry, volatile raw material and energy costs, and intense competition. Its ability to maintain cost leadership, manage environmental compliance effectively, and potentially diversify its product mix will be key to navigating these challenges and ensuring sustained performance.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 82 | 77 | 82 | 84 | 92 | 92 | 77 | 68 | 75 | 73 |
| Other Income | 2 | 3 | 1 | 3 | 1 | 1 | 2 | 3 | 3 | 2 |
| Total Income | 84 | 79 | 82 | 86 | 94 | 93 | 78 | 71 | 78 | 75 |
| Total Expenditure | 70 | 68 | 72 | 72 | 79 | 80 | 71 | 66 | 66 | 63 |
| Operating Profit | 14 | 11 | 11 | 14 | 15 | 13 | 7 | 5 | 11 | 12 |
| Interest | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 6 | 7 | 9 | 10 | 11 | 6 | 7 | 7 | 8 | 8 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -10 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 8 | 3 | 1 | 4 | -7 | 5 | -1 | -5 | 1 | 2 |
| Provision for Tax | 3 | 2 | 1 | 2 | 2 | 2 | 1 | -0 | 1 | -4 |
| Profit After Tax | 5 | 1 | -1 | 2 | -9 | 3 | -2 | -4 | 0 | 6 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 | -0 |
| Profit After Adjustments | 5 | 1 | -1 | 2 | -9 | 3 | -2 | -4 | 0 | 6 |
| Adjusted Earnings Per Share | 3.8 | 0.6 | -0.4 | 1.3 | -6.4 | 1.8 | -1.4 | -3.1 | 0.3 | 4 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Net Sales | 205 | 181 | 272 | 331 | 327 | 334 | 311 | 293 |
| Other Income | 3 | 1 | 6 | 6 | 9 | 7 | 9 | 10 |
| Total Income | 208 | 182 | 277 | 337 | 336 | 341 | 320 | 302 |
| Total Expenditure | 149 | 157 | 215 | 221 | 273 | 290 | 284 | 266 |
| Operating Profit | 59 | 25 | 62 | 116 | 63 | 51 | 36 | 35 |
| Interest | 4 | 3 | 1 | 1 | 2 | 5 | 8 | 8 |
| Depreciation | 25 | 20 | 22 | 23 | 22 | 36 | 28 | 30 |
| Exceptional Income / Expenses | -3 | 0 | 0 | -3 | 0 | -10 | 0 | 0 |
| Profit Before Tax | 27 | 2 | 39 | 89 | 39 | -0 | -0 | -3 |
| Provision for Tax | 1 | 10 | 10 | 25 | 13 | 7 | 3 | -2 |
| Profit After Tax | 25 | -8 | 29 | 65 | 26 | -7 | -3 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 25 | -8 | 29 | 65 | 26 | -7 | -3 | 0 |
| Adjusted Earnings Per Share | 18.3 | -5.8 | 20.3 | 45.5 | 18.5 | -4.8 | -2.4 | -0.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -7% | -2% | 11% | 0% |
| Operating Profit CAGR | -29% | -32% | 8% | 0% |
| PAT CAGR | 0% | NAN% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -43% | -4% | 11% | NA% |
| ROE Average | -1% | 1% | 7% | 6% |
| ROCE Average | 2% | 4% | 11% | 9% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 276 | 267 | 298 | 361 | 387 | 380 | 375 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 22 | 23 | 0 | 0 | 16 | 64 | 81 |
| Other Non-Current Liabilities | -37 | -10 | -6 | 3 | 9 | 16 | -9 |
| Total Current Liabilities | 76 | 42 | 58 | 68 | 122 | 103 | 144 |
| Total Liabilities | 337 | 322 | 349 | 433 | 535 | 563 | 592 |
| Fixed Assets | 195 | 202 | 194 | 192 | 247 | 317 | 387 |
| Other Non-Current Assets | 64 | 44 | 56 | 95 | 157 | 96 | 47 |
| Total Current Assets | 78 | 76 | 89 | 141 | 126 | 127 | 121 |
| Total Assets | 337 | 322 | 349 | 433 | 535 | 563 | 592 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 0 | 23 | 33 | 69 | 7 | 19 |
| Cash Flow from Operating Activities | 54 | 45 | 55 | 93 | 31 | 40 | 38 |
| Cash Flow from Investing Activities | -58 | -6 | -21 | -48 | -110 | -86 | -81 |
| Cash Flow from Financing Activities | 3 | -16 | -25 | -9 | 16 | 59 | 31 |
| Net Cash Inflow / Outflow | -1 | 23 | 9 | 36 | -62 | 13 | -12 |
| Closing Cash & Cash Equivalent | 0 | 23 | 33 | 69 | 7 | 19 | 8 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 18.26 | -5.78 | 20.34 | 45.54 | 18.5 | -4.83 | -2.38 |
| CEPS(Rs) | 36.27 | 8.6 | 36.06 | 61.71 | 34.21 | 20.46 | 17.39 |
| DPS(Rs) | 1.25 | 0 | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
| Book NAV/Share(Rs) | 197.46 | 189.72 | 210.18 | 253.86 | 271.02 | 264.35 | 261.18 |
| Core EBITDA Margin(%) | 27.11 | 13.05 | 20.84 | 33.3 | 16.56 | 13.17 | 8.71 |
| EBIT Margin(%) | 14.8 | 2.65 | 14.78 | 27.07 | 12.46 | 1.54 | 2.45 |
| Pre Tax Margin(%) | 13.06 | 1.12 | 14.37 | 26.91 | 11.92 | -0.09 | -0.06 |
| PAT Margin (%) | 12.44 | -4.5 | 10.56 | 19.43 | 8.02 | -2.06 | -1.09 |
| Cash Profit Margin (%) | 24.71 | 6.69 | 18.73 | 26.33 | 14.83 | 8.74 | 7.93 |
| ROA(%) | 7.56 | -2.47 | 8.56 | 16.52 | 5.44 | -1.26 | -0.59 |
| ROE(%) | 9.25 | -3 | 10.2 | 19.66 | 7.06 | -1.81 | -0.91 |
| ROCE(%) | 9.52 | 1.56 | 13.34 | 27.01 | 10.67 | 1.2 | 1.61 |
| Receivable days | 17.03 | 24.94 | 24.55 | 23.71 | 23.88 | 22.78 | 25.96 |
| Inventory Days | 15.17 | 17.96 | 14.17 | 15.8 | 18.32 | 23.44 | 30.73 |
| Payable days | 164.65 | 147.56 | 87.1 | 125.44 | 102.16 | 108.99 | 112.58 |
| PER(x) | 5.1 | 0 | 12.32 | 4.93 | 35.04 | 0 | 0 |
| Price/Book(x) | 0.47 | 0.66 | 1.19 | 0.88 | 2.39 | 2.67 | 1.13 |
| Dividend Yield(%) | 1.34 | 0 | 0.5 | 0.56 | 0.19 | 0.18 | 0.42 |
| EV/Net Sales(x) | 0.83 | 1.13 | 1.3 | 0.95 | 2.8 | 3.26 | 1.75 |
| EV/Core EBITDA(x) | 2.89 | 8.18 | 5.66 | 2.71 | 14.48 | 21.23 | 15.09 |
| Net Sales Growth(%) | 0 | -11.59 | 50.21 | 22.01 | -1.23 | 2.16 | -6.98 |
| EBIT Growth(%) | 0 | -84.15 | 738.77 | 123.64 | -54.53 | -87.31 | 49.06 |
| PAT Growth(%) | 0 | -131.96 | 453.52 | 124.66 | -59.24 | -126.37 | 50.63 |
| EPS Growth(%) | 0 | -131.67 | 451.69 | 123.9 | -59.37 | -126.11 | 50.66 |
| Debt/Equity(x) | 0.15 | 0.12 | 0.02 | 0 | 0.05 | 0.22 | 0.33 |
| Current Ratio(x) | 1.03 | 1.82 | 1.55 | 2.08 | 1.03 | 1.23 | 0.84 |
| Quick Ratio(x) | 0.92 | 1.6 | 1.34 | 1.83 | 0.9 | 0.97 | 0.66 |
| Interest Cover(x) | 8.52 | 1.73 | 35.85 | 173.69 | 23.3 | 0.94 | 0.97 |
| Total Debt/Mcap(x) | 0.33 | 0.17 | 0.02 | 0 | 0.02 | 0.08 | 0.29 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.88 | 72.63 | 72.57 | 72.18 | 72.18 | 72.18 | 72.13 | 72.13 | 72.13 | 72.13 |
| FII | 0.27 | 0.11 | 0.03 | 0.03 | 0.02 | 0 | 0.08 | 0.04 | 0.04 | 0.04 |
| DII | 0.08 | 0.08 | 0.27 | 0.27 | 0.27 | 0.34 | 0.28 | 0.17 | 0.14 | 0.07 |
| Public | 26.77 | 27.19 | 27.12 | 27.51 | 27.53 | 27.48 | 27.5 | 27.65 | 27.69 | 27.75 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.38 | 0.39 | 0.39 | 0.4 | 0.4 | 0.39 | 0.4 | 0.4 | 0.4 | 0.4 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.42 | 1.43 | 1.43 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -7% | -2% | +11% | — |
| Operating Profit CAGR | -29% | -32% | +8% | — |
| PAT CAGR | — | 0% | — | — |
| Share Price CAGR | -43% | -4% | +11% | — |
| ROE Average | -1% | +1% | +7% | +6% |
| ROCE Average | +2% | +4% | +11% | +9% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.88 | 72.63 | 72.57 | 72.18 | 72.18 | 72.18 | 72.13 | 72.13 | 72.13 | 72.13 |
| FII | 0.27 | 0.11 | 0.03 | 0.03 | 0.02 | 0 | 0.08 | 0.04 | 0.04 | 0.04 |
| DII | 0.08 | 0.08 | 0.27 | 0.27 | 0.27 | 0.34 | 0.28 | 0.17 | 0.14 | 0.07 |
| Public | 26.77 | 27.19 | 27.12 | 27.51 | 27.53 | 27.48 | 27.5 | 27.65 | 27.69 | 27.75 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.38 | 0.39 | 0.39 | 0.4 | 0.4 | 0.39 | 0.4 | 0.4 | 0.4 | 0.4 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.42 | 1.43 | 1.43 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.